CFDE Data Portal | Search PIWIL4-AS1

	Label	Description
	PIWIL4-AS1 Gene (Entity type)	ENSG00000255929 - PIWIL4 antisense RNA 1
	GSE240439 decitabine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE199107 tryptophan 6 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 6 V 5 ETOPOSIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE171692 FXN knockdown 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE114883 0 V 5 ROMIDEPSIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE149901 3 V 1 ANLOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE140322 0 V 2 IMATINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

PIWIL4-AS1

ENSG00000255929 - PIWIL4 antisense RNA 1

GSE240439 decitabine 1 v 2 human up

A Gene Set from LINCS

GSE199107 tryptophan 6 v 7 human up

A Gene Set from LINCS

GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 0 v 1 human up

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn

A Gene Set from LINCS

GSE120612 6 V 5 ETOPOSIDE HUMAN DN

A Gene Set from LINCS

GSE171692 FXN knockdown 1 v 0 human up

A Gene Set from LINCS

GSE114883 0 V 5 ROMIDEPSIN HUMAN DN

A Gene Set from LINCS

GSE149901 3 V 1 ANLOTINIB HUMAN DN

A Gene Set from LINCS

GSE140322 0 V 2 IMATINIB HUMAN DN

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.